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A B S T R A C T   
Oligomers which form during amyloid fibril assembly are considered to be key contributors towards amyloid 
disease. However, understanding how such intermediates form, their structure, and mechanisms of toxicity 
presents significant challenges due to their transient and heterogeneous nature. Here, we discuss two different 
strategies for addressing these challenges: use of (1) methods capable of detecting lowly-populated species within 
complex mixtures, such as NMR, single particle methods (including fluorescence and force spectroscopy), and 
mass spectrometry; and (2) chemical and biological tools to bias the amyloid energy landscape towards specific 
oligomeric states. While the former methods are well suited to following the kinetics of amyloid assembly and 
obtaining low-resolution structural information, the latter are capable of producing oligomer samples for high- 
resolution structural studies and inferring structure-toxicity relationships. Together, these different approaches 
should enable a clearer picture to be gained of the nature and role of oligomeric intermediates in amyloid for-
mation and disease.   
1. Introduction 
Amyloid fibril formation is a complex and multifaceted process, 
characterized by the self-assembly of proteins or peptides into insoluble 
cross-β deposits [1,2] (Fig. 1A). In healthy individuals, amyloid assem-
bly pathways are highly regulated and accessible only to a small number 
of proteins, resulting in fibrils which can play important functional roles. 
These so-called “functional amyloid” fibrils can act as structural scaf-
folds, protein reservoirs, biofilm components, or be involved in the 
laying down and storage of long-term memories, amongst other bio-
logical roles [3,4]. However, normally soluble proteins and peptides can 
also be rendered amyloid-competent by specific mutations, changes to 
post-translational modifications, or changes to the intra- or extracellular 
conditions [1]. The aberrant and unregulated self-assembly events 
which subsequently occur are associated with an array of human dis-
orders, ranging from Alzheimer’s and Parkinson’s diseases, to type II 
diabetes and dialysis-related amyloidosis [1,2]. 
For many disease-associated amyloid proteins, it has been recog-
nized that soluble oligomers which form during, or as a result of, fibril 
assembly can be the major cytotoxic species associated with cellular 
dysfunction and disease onset [5–10]. Consequently, there has been 
intense interest in the study of such assembly intermediates, with the 
aim to better understand the molecular mechanism(s) by which soluble 
oligomers form and transition into a cross-β structure, as well as to 
identify structural features associated with cytotoxicity [11]. Unfortu-
nately, the complexity and heterogeneity of amyloid assembly pathways 
makes such analyses immensely challenging in vitro, let alone in vivo. 
Additionally, it is difficult to reconcile the vast range of oligomers 
observed by different research groups under varying experimental 
conditions. Oligomeric intermediates are typically metastable, lowly- 
populated, and interconverting with each other and fibril surfaces 
within the aggregating mixture [12,13]. As a consequence, the proper-
ties of specific oligomers cannot be readily determined in detail using 
most bulk solution methods, as such approaches typically do not allow 
information to be extracted about individual species within these 
diverse populations. The structural and kinetic study of oligomeric in-
termediates thus requires the use of techniques capable of dissecting the 
properties of individual species within complex mixtures, coupled with 
careful data analysis to extract the relevant information about their 
population, lifetime, and structural features. Some of the most powerful 
methods include those which can directly detect single particles (such as 
single particle fluorescence, e.g. fluorescence resonance energy transfer 
(FRET) [14,15], and single particle force spectroscopy (SPFS) [16]) or 
single species (such as electrospray ionization mass spectrometry (ESI- 
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MS) [17–20]). Solution-phase nuclear magnetic resonance (NMR) 
spectroscopy, which is unique amongst ensemble techniques for its 
ability to extract structural and kinetic information about different 
protein populations in atom-specific detail, can also be used for the 
characterization of lowly populated and rapidly interconverting species 
[21]. Additionally, molecular dynamics simulations using a variety of 
different force fields and approaches can provide insights into the po-
tential repertoire of oligomers formed, which then require parallel ex-
periments for their verification [22–26]. However, the aforementioned 
experimental approaches are not without their limitations – in 
particular, the structural resolution obtained using these techniques is 
generally insufficient to inform rational drug design approaches. Thus, 
there remains an on-going need to explore complementary methods for 
the characterization of amyloid oligomers. 
The purposeful manipulation of an amyloidogenic system, with the 
aim of tuning the self-assembly landscape to favor specific events or 
species of interest, represents an alternative strategy for the study of 
amyloid self-assembly. Such an approach can reduce sample heteroge-
neity and, if used to bias the system towards oligomer formation, may 
allow mechanistic and structural information to be obtained about these 
Fig. 1. Understanding the complex mechanisms of amyloid fibril assembly using “non-perturbing” biophysical methods. A: A schematic of a generic protein self- 
assembly pathway. The self-association of particular proteins can lead to the formation of cross-β fibrillar structures (amyloid fibrils) but can also lead to the for-
mation of aggregates which lie “off-pathway” from fibril assembly. Assembly intermediates are often lowly-populated, rapidly interconverting, and transiently 
formed, making them challenging targets for many biophysical techniques, with notable exceptions being NMR (B, C) [31–35] and methods which detect single 
particles or species (D, E) (e.g. single particle fluorescence - including FRET and 2-color incidence detection, TCCD - [36,37], SPFS [38], and ESI-MS [39–41]). 
Monomer-oligomer exchange rates and oligomer populations (poligomer) can be obtained through the global fitting of oligomerization models to the observed NMR or 
single particle data (B, D). The structural information obtained through NMR and single particle/species methods is typically of low resolution but can provide 
insights into oligomerization interfaces (C), and structural transitions (E). The DEST and PRE data shown in B and C, respectively, were simulated by numerically 
solving the corresponding McConnell equations using a B1 field of 200 Hz, R2B = 1000 s− 1, R2A = 10 s− 1, and R1A = 1.5 s− 1. The PRE data shown in C were simulated 
with a distance between residue 160 and the MTSL label (on residue 20) of 1 Å in the excited state (5% population). The black line in the collisional cross-section plot 
in E represents the expected cross-sections for each oligomer size, assuming isotropic growth, and the dashed red box indicates the point in the self-assembly pathway 
at which the oligomers of this protein start to undergo structural transitions, as detected by IMS coupled to ESI-MS [17,41]. (For interpretation of the references to 
color in this figure legend, the reader is referred to the web version of this article.) 
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assembly intermediates using a wider range of techniques than would 
otherwise be possible. Modulation of amyloid assembly can be achieved 
through the use of small molecule ligands, antibodies, or covalent pro-
tein modifications, to generate samples with a range of defined oligomer 
populations. In combination with methods such as NMR, kinetic 
modelling, and cell toxicity assays, these samples can provide insights 
into the role, disease-relevance, and structure of particular oligomeric 
populations, and validate potential routes for the treatment of amyloid 
diseases. There are now several examples where the stabilization (or 
destabilization) of specific species has reduced heterogeneity suffi-
ciently to facilitate detailed structural studies using X-ray crystallog-
raphy, thereby providing high-resolution insights into these potential 
therapeutic targets [27–30]. 
This review provides an overview of the experimental methods and 
approaches which can be used to study the structure, kinetics, and 
disease-relevance of transient amyloid oligomers, and provides exam-
ples of their use in vitro. Although the ultimate goal of the amyloid field 
is to perform these experiments in vivo, in vitro studies allow us to 
explore the energy landscape of amyloid protein self-assembly and 
identify general trends between certain structural features (e.g. hydro-
phobicity, secondary structure) and toxicity. We discuss approaches 
through which observations can be made without intentional pertur-
bation of the self-assembly process (e.g. using solution NMR, single 
particle methods, and native ESI-MS), as well as those through which the 
self-assembly equilibrium is deliberately modified to gain information 
about specific species. These “non-perturbing” and “perturbing” 
methods are complementary: most non-perturbing techniques are best 
suited to the determination of kinetic parameters (yielding information 
about rates of interconversion and population lifetimes), while the res-
olution of structural information they can obtain is typically lower. By 
contrast, perturbing methods offer the opportunity to analyze species 
using high-resolution structural methods, and hence enable detailed 
structure-toxicity relationships to be determined. The combination of 
both of these approaches provides an ideal experimental toolkit for 
generating more complete descriptions of the molecular mechanisms of 
amyloid fibril formation and their associated cellular toxicity. 
2. Non-perturbing methods for the study of amyloid oligomers 
2.1. Solution NMR 
NMR spectroscopy has the capability to characterize transient and 
heterogeneous systems in all-atom detail, and thus has been widely 
utilized in the characterization of amyloid protein assembly [21,42,43]. 
Many powerful NMR methods are sensitive to the properties of “NMR- 
invisible” species (i.e. those <1% populated or of high molecular 
weight) that are in rapid exchange with the NMR-visible state(s) 
[21,44]. In the context of amyloid assembly, this means that the prop-
erties (e.g. size, timescale of formation) of lowly populated (ca. 
0.5–15%) amyloid oligomers can be indirectly studied via the mono-
meric precursor, using experiments such as Carr-Purcell-Meiboom-Gill 
(CPMG) relaxation dispersion, chemical exchange saturation transfer 
(CEST), paramagnetic relaxation enhancement (PRE), life-time line 
broadening, dark exchange saturation transfer (DEST), and off- 
resonance R1ρ relaxation [42]. Using these methods, the relative pop-
ulations and exchange rates (100–10,000 s− 1) between species can be 
extracted, providing valuable information about the assembly process. 
Some experiments (e.g. CPMG relaxation dispersion and CEST) are 
designed to probe exchange with species whose relaxation properties are 
not very different to those of the monomer, and thus are best suited to 
the study of small oligomers [45–47]. By contrast, others, such as DEST, 
life-time line broadening, and off-resonance R1ρ [33], require exchange 
of the monomer with a higher molecular weight species, making them 
ideal for the study of large amyloid oligomers or the exchange between 
monomer and fibrils [32,48]. 
The application of these NMR methods, in combination with global 
fitting of data acquired at a range of protein concentrations and mag-
netic field strengths, can provide valuable insights into the mechanisms 
of self-assembly (Fig. 1B). Such an approach has recently been used to 
interrogate the early stages of aggregation of a minimal peptide from the 
protein huntingtin (associated with Huntington’s disease), providing 
information about the populations, exchange rates, and secondary 
structure of oligomers formed by two competing aggregation pathways 
[31]. Similar strategies have been adopted for other amyloid proteins 
that form a range of oligomeric states and structures, revealing insights 
into the binding of amyloid β (Aβ) monomers to fibrils [49], the energy 
landscape of copper‑zinc superoxide dismutase (SOD1) aggregation 
[50], and the formation of β2-microglobulin (β2m) oligomers [35,51] – 
events which are associated with Alzheimer’s disease, amyotrophic 
lateral sclerosis, and dialysis-related amyloidosis, respectively. Howev-
er, as these methods rely on reversible chemical exchange, this places a 
limit on the protein concentrations which can be used. There is an 
apparent irreversibility of the amyloid pathway for samples prepared 
above their critical protein concentration, and so sample conditions 
must be carefully selected to minimize the formation of any highly 
aggregation-prone species, while maintaining a suitable signal-to-noise 
ratio. 
An alternative NMR approach that can be used to study the assembly 
of amyloid oligomers involves tilting the energy landscape of aggrega-
tion in a controlled manner through the use of hydrostatic pressure [34]. 
Pressure allows the rapid disassembly of oligomeric species before they 
convert to pressure-resistant fibrils. This technique therefore permits 
study of the oligomerization equilibria that would not be accessible to 
the experiments described above under a constant atmospheric pressure. 
Pressure-jump NMR experiments, in which the pressure inside the NMR 
cell is rapidly altered (in a matter of milliseconds), have been used 
recently to study the interconversion of a highly unfolded Aβ monomer 
(at high pressure) with an oligomeric species (at low pressure), 
providing residue-specific information about oligomers that show the 
first signs of conversion into amyloid [34]. 
In addition to probing the kinetics of protein self-assembly, NMR can 
also be used to investigate the structural properties of amyloid oligomers 
[31,52–54]. NMR-derived structural insights into these protein com-
plexes can be achieved through the determination of distance restraints 
from NMR experiments, which are then used to drive simulated 
annealing calculations [55] or other molecular dynamics approaches 
[56]. Due to the transient nature of the complexes present in the early 
stages of amyloid assembly, traditional nuclear Overhauser effect-based 
structural investigations typically fail and intermolecular distance re-
straints tend to instead be derived from PRE studies using paramagnetic 
spin labels (commonly MTSL; S-(1-oxyl-2,2,5,5-tetramethyl-2,5-dihy-
dro-1H-pyrrol-3-yl)methyl methanesulfonothioate) [57] (Fig. 1C). 
When covalently attached at a specific site on a protein’s surface, spin 
labels can be used to map oligomerization interfaces, even those that are 
short-lived (< 100 μs) [58]. Data from PRE experiments have been used 
to generate structural models of β2m dimers and hexamers [35,52] 
(Fig. 1C), tetramers formed by a minimal huntingtin construct [31], and 
homo-/heterodimers formed by α- and β-synuclein (the former variant 
being associated with Parkinson’s disease) [53,54]. 
Due to the size limitations of solution NMR methods, it has remained 
challenging to investigate large oligomeric assemblies directly using 
solution NMR-based approaches. However, with the advance of 13C- 
methyl-TROSY methods as sensitive reporters of protein structure and 
dynamics, amyloid oligomers can be studied directly (provided that they 
exist in a sufficiently large population) [59]. Finally, the arsenal of 
magnetic resonance techniques to study amyloid formation would not 
be complete without mentioning solid-state NMR and electron para-
magnetic resonance (EPR). Both techniques have contributed substan-
tially to our understanding of the structures of amyloid fibrils [60,61], as 
well as oligomers of Aβ peptides [62,63] and α-synuclein [64], but are 
frequently geared towards stable, monodisperse samples (e.g. fibrils or 
stable oligomers), with some notable exceptions [65,66]. 
E.E. Cawood et al.                                                                                                                                                                                                                              
Biophysical Chemistry 268 (2021) 106505
4
NMR currently remains the only ensemble method that can yield 
atom-specific structural and kinetic information (including rates of 
interconversion and lifetimes) for lowly populated, transient states, by 
observing their effect on the main species in solution (usually the 
monomer). However, rather than inferring such information from the 
interpretation of NMR data, it is also possible to directly observe tran-
sient, oligomeric species using single particle and other non-ensemble 
averaged methods, as described below. 
2.2. Single particle and non-ensemble averaged methods 
Single particle techniques are unparalleled in their ability to directly 
detect individual molecules and populations of interconverting species 
within heterogeneous mixtures. Single particle fluorescence methods (a 
term we use here to describe approaches which rely on fluorescent dyes, 
rather than the measurement of intrinsic protein fluorescence) and SPFS 
have both played key roles in the amyloid field, allowing kinetic and 
low-resolution structural information to be obtained for the species 
populated during fibril assembly [67–69]. Other non-ensemble averaged 
methods, such as ESI-MS, are also able to directly detect specific olig-
omer populations during assembly. When coupled to other techniques 
(e.g. ion mobility spectrometry, hydrogen-deuterium exchange, or 
infrared spectroscopy), ESI-MS is capable of providing structural infor-
mation for these individual oligomeric species [18,19]. 
Single particle fluorescence experiments used for the study of amy-
loid assembly most commonly require preparation of dual-labelled 
protein samples, containing an equimolar mixture of protein mole-
cules labelled with one of two distinct fluorescent dyes [67]. From such 
dual-labelled samples, oligomers can be detected by the observation of 
simultaneous bursts from the two fluorophores or, in cases where the 
emission of one fluorophore overlaps with the absorption of the other, 
by the ability of these molecules to undergo FRET (Fig. 1D) 
[10,36,37,70–80]. Different oligomer populations can be distinguished 
from one another based on the intensity of fluorescent bursts [79,80], 
the FRET efficiency [10,36,37], or the stability of the detected oligomers 
to particular experimental conditions (e.g. dilution into buffer with high 
or low ionic strengths, or the presence of proteases) 
[10,37,75,76,79,81]. By using such measurements to monitor the pop-
ulation of specific oligomers in an aggregating mixture over time, the 
resulting data can be fitted to self-assembly models to determine the 
rates of oligomer formation and interconversion, as well as thermody-
namic parameters for these protein-protein interactions 
[36,37,76,78,82] (Fig. 1D). 
While single particle fluorescence is immensely powerful, like any 
technique it relies on certain assumptions and has various limitations. 
The requirement to perform single particle fluorescence measurements 
under highly dilute solution conditions (several orders of magnitude less 
concentrated than the conditions ordinarily used to study protein ag-
gregation in vitro) can limit the types of oligomers which can be 
observed. Typically, aliquots from a more concentrated aggregating 
mixture are taken and diluted immediately prior to single particle ex-
periments, and thus unstable and/or highly transient oligomers may 
dissociate before the data are acquired [79]. However, this issue can be 
minimized through the use of microfluidic devices to speed up sample 
analysis [75,83] or by diluting aliquots into a solution of non- 
fluorescently labelled protein, rather than buffer alone [10]. An addi-
tional factor which must be considered is that most single particle 
fluorescence experiments make use of fluorescently-labelled protein 
samples, and therefore rely on the assumption that the incorporation of 
fluorescent dyes, which are often large and hydrophobic, does not per-
turb the assembly mechanism. This assumption may not always hold 
true [84–86], and the appropriate selection of fluorophores must be 
ensured by performing thorough control experiments. It is also possible 
to perform experiments with fluorescent probes which interact non- 
covalently with the protein of interest, and which can therefore be 
added after assembly has taken place [81,82,87,88]. 
SPFS relies on the use of mechanical force to perturb interatomic 
interactions and has been extensively used to study the formation of 
native protein contacts during folding [89]. However, non-native 
intermolecular contacts that take place during protein misfolding and 
self-assembly can also be studied through such methods. Atomic force 
microscopy (AFM) is the primary SPFS technique which has been used to 
study amyloid assembly, as the high forces accessible in this method are 
suitable for the study of amyloidogenic oligomerization events [16]; 
lower forces can be accessed using other, complementary SPFS methods 
[90], such as optical tweezers [91–94]. Unlike single particle fluores-
cence measurements, where soluble oligomers formed at any stage 
during aggregation can be detected within a single experiment, AFM 
SPFS experiments tend to be designed to focus on specific oligomeriza-
tion events – commonly dimerization. The lowering and raising of an 
AFM cantilever to and from a surface controls the formation and then 
drives dissociation of individual interactions [95]. For the study of 
dimerization events, one protein is typically attached to the cantilever 
tip, whilst the partner of interest (often the same protein) is immobilized 
on a surface on the sample stage [96–108]. Formation of higher oligo-
mers can be studied using tandem repeat oligomers which are tethered 
between the surface and cantilever tip [109] or, more recently, using the 
flexible nanoarray (FNA) approach where a number of monomers are 
immobilized at various points along a flexible polymer [110–113]. In 
both cases, the site of covalent attachment and the length/flexibility of 
the covalent linker need to be carefully selected to ensure that steric 
constraints do not alter the accessibility of key interaction interfaces or 
change the behavior of the protein. SPFS methods can yield information 
concerning the lifetime of specific protein-protein interactions and their 
strength (force resistance). Furthermore, the distance required to move 
the cantilever away from the surface to cause disruption of the oligomer 
can be used to infer the site of interaction [95,114]. 
In addition to its use as a SPFS method, AFM can be used as a surface- 
imaging technique to directly observe the formation and turnover of 
oligomers during amyloid assembly [68]. Recently, AFM has been 
coupled with infrared spectroscopy (AFM-IR) to image the secondary 
structure content of individual amyloid oligomers at the single aggre-
gate level and to identify structural transitions which occur during the 
self-assembly of various amyloid proteins, including ataxin-3 (the 
causative agent of spinocerebellar ataxia type-3 or Machado–Joseph 
disease) [38], huntingtin exon 1 [115], and α-synuclein [116] (Fig. 1E). 
Such conformational conversion events are often rate-limiting steps in 
amyloid formation [117], and thus are key processes to characterize in 
structural and kinetic detail. 
ESI-MS represents an alternative technique for the direct detection of 
individual monomeric conformers and oligomeric species formed during 
amyloid assembly. As a soft ionization method, ESI allows non-covalent 
interactions to be maintained when aggregating proteins are sprayed 
into a mass spectrometer from a volatile buffer solution [118]. ESI-MS 
has the advantage over the single particle methods discussed here in 
that no dye labels or immobilization strategies are required, with the 
mass accuracy of modern mass spectrometers making it straightforward 
to detect different oligomeric species that are co-populated [17–20]. 
Most powerfully, ESI-MS can be directly coupled to other methods, such 
as ion mobility spectrometry (IMS; which allows oligomers with the 
same m/z ratio to be separated based on size and shape) [41,119–133], 
hydrogen-deuterium exchange and related covalent labelling experi-
ments (revealing oligomer interfaces) [134–147], and infrared spec-
troscopy (IR) [39,40] to yield structural information about the different 
species present in an aggregating mixture. These techniques have been 
used to detect structural transitions in amyloid assembly pathways 
[39–41,123,135] (Fig. 1E), produce low-resolution structural models of 
specific intermediates [144,145,148], and infer the role of different 
oligomers in amyloid assembly and toxicity [120,130]. 
The primary limitation of methods which detect single particles or 
populations is their structural resolution. Unlike NMR, these techniques 
do not readily reveal residue- or atom-level information about amyloid 
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assembly, and thus cannot facilitate structure-based ligand design ap-
proaches. We note, however, that the recent revolution in cryo-electron 
microscopy (cryo-EM), including advances in image processing algo-
rithms, has allowed individual species within heterogeneous samples to 
be studied at high resolution [149]. While cryo-EM has already played a 
key role in the elucidation of fibril structures at near-atomic resolution 
[150], there are few examples of its application to amyloid oligomers 
[8]. This technique nonetheless has the potential to be used in the future 
to reveal high-resolution structural information for oligomeric samples 
at a “single species” level. 
NMR and single particle methods remain invaluable for detecting 
individual oligomer populations and elucidating amyloid pathways. 
These approaches, in combination with methods which allow access to 
higher-resolution information (discussed below), facilitate progress to-
wards more refined descriptions of amyloid assembly pathways. 
3. Trapping transient oligomers to facilitate the 
characterization of amyloid self-assembly 
Obtaining high-resolution structural and functional insights into 
specific amyloid oligomers typically requires the use of samples which 
predominantly contain a single species. While it is possible to reduce the 
heterogeneity of oligomer samples through size separation approaches 
[151], the degree of sample homogeneity achievable through this 
method is limited, as the self-assembly landscape may start to rapidly re- 
equilibrate after isolation of individual species. Careful control of sam-
ple preparation conditions (e.g. the availability of air-water interfaces, 
or buffer composition and pH) can bias self-assembly landscapes to-
wards specific oligomeric states (Section 3.1), but the resulting oligomer 
distributions are often broad. Furthermore, such an approach does not 
address the experimental challenges which remain concerning how to 
trap and kinetically/structurally characterize amyloid intermediates in 
an in vivo setting. Four primary tools have emerged which can favor the 
production of narrow distributions of oligomers, or sometimes even a 
specific oligomer state, without requiring specific buffer conditions: 
oligomer-binding antibodies (Section 3.2), non-covalent small molecule 
ligands (Section 3.3), covalent ligands or protein modifications (Section 
3.4), and crosslinking (Section 3.5). 
3.1. Sample preparation strategies 
For certain amyloid proteins, different sample preparation strategies 
have been established which have been shown to favor specific oligomer 
distributions. Lyophilization, followed by resuspension and incubation 
at high protein concentrations, has been used to promote the formation 
of kinetically-trapped α-synuclein oligomers that can then be further 
enriched by centrifugation, size-exclusion chromatography, or other size 
separation methods [152]. While oligomer distributions produced by 
this approach are still broad (predominantly 10-40mers, although spe-
cies up to 90mers have been detected) [8,153,154], the enrichment of 
oligomers in these samples has nonetheless facilitated their study via a 
range of biophysical techniques [8,136,138,153–158]. Notably, lyoph-
ilization has been used to produce α-synuclein samples for cryo-EM, 
leading to two low-resolution (18–19 Å) reconstructions of toxic cylin-
drical oligomers [8], and solid-state NMR, where structural properties of 
these same oligomers were compared with those of non-toxic, small 
molecule-stabilized oligomers [159] to understand the structural de-
terminants of oligomer toxicity [64]. Similarly, samples prepared 
through incubation of amyloid proteins in carefully-selected buffers 
have allowed structure-toxicity relationships to be uncovered for olig-
omers formed by the N-terminal domain of the Escherichia coli HypF 
protein (prepared in additive-containing solutions) [160,161] and Aβ 
peptides (prepared in low salt buffers at low temperature [162,163] or 
in the presence of detergent micelles [26,164]), amongst others. In 
general, such studies have highlighted that structural features which 
promote promiscuous interactions with other cellular components (e.g. 
enhanced surface hydrophobicity or the presence of structured elements 
which can insert into membranes) are often associated with toxicity 
[26,64,165,166], while the proportion of β-sheet structure does not 
generally appear to play a clear role [167]. 
3.2. Using antibodies to probe the structure and toxicity of oligomers 
An emerging therapeutic avenue for the treatment of amyloid dis-
eases is the use of antibodies to capture and neutralize toxic oligomers, 
due to the ability of these proteins to bind target epitopes with high 
specificity and affinity [168,169]. Such molecular recognition proper-
ties also make antibodies ideal tools for stabilizing specific, transient 
amyloid intermediates for detailed study [170,171] and for detecting 
the presence of particular structural features [172]. The A11 antibody, 
in particular, has played an important role in the amyloid field [6]. 
Although A11 was raised against an oligomeric mimic of Aβ40 (in the 
form of gold nanoparticles coated with Aβ40 peptides), this polyclonal 
antibody recognizes pre-fibrillar, toxic oligomers formed by a range of 
amyloid proteins with diverse primary sequences and native folds, 
suggesting that toxicity is associated with a common set of structural 
features [6]. Understanding precisely what these structural features are, 
how much they vary between different amyloid proteins, and which 
oligomeric species within a given self-assembly pathway possess these 
characteristics is still not understood. 
In addition to antibodies which recognize specific structural features 
in a sequence-independent manner [6], antibodies (and antibody frag-
ments) which bind to, and stabilize, specific oligomers formed by 
different amyloid proteins have also been developed: this includes an-
tibodies which target oligomers of α-synuclein (SDS-stable dimers/tet-
ramers [173] and SDS-stable trimers/hexamers [174]), Aβ (< 70 kDa 
oligomers [175,176] and larger aggregates [177]), and a truncated β2m 
variant (dimers [28]; Fig. 2A). Antibodies have also been developed that 
interfere with specific stages of amyloid assembly for particular proteins 
[178]. To guarantee specificity for amyloid oligomers (over monomers 
or fibrils), antibodies are often generated by screening against samples 
which have been enriched in oligomers [173,174,177], by screening 
against cyclic peptides which mimic predicted oligomer epitopes 
[175,176], by grafting amyloidogenic peptide fragments into the 
complementary-determining regions of canonical antibody scaffolds 
[179,180], or through rational in silico design methods [178,181]. The 
ability of antibodies generated using these approaches to bind oligomers 
in cell models or in ex vivo samples highlights the physiological- and/or 
disease-relevance of these antibody-stabilized structures, and in some 
cases has allowed the roles of specific oligomer sub-classes in disease to 
be interrogated [174–178,181,182]. Oligomer-binding antibodies have 
also been used to facilitate structural studies of amyloid intermediates – 
this has been demonstrated by a nanobody-stabilized dimer formed by a 
truncated β2m variant (ΔN6-β2m; Fig. 2A) [28] and a tetrameric fusion 
between an antibody and an Aβ peptide fragment [183], both of which 
yielded high-resolution crystal structures. Thus, in contrast with other 
approaches discussed thus far in this review, antibody-oligomer com-
plexes have the potential to provide high-resolution insights into the 
conformational changes which an amyloid protein undergoes during the 
initiation of self-assembly. Where it is possible to assess the toxicity of 
such stabilized oligomer complexes, structural features that are associ-
ated with disease can be inferred. 
3.3. Stabilizing oligomers using non-covalent small molecules 
Non-covalent small molecules offer an alternative approach to cap-
ture amyloidogenic intermediates. In a similar manner to antibodies 
[178], such ligands can be invaluable tools to interfere with distinct 
microscopic events in amyloid self-assembly [184–187], although 
identification of such compounds is complicated by the poor ligand-
ability of most monomeric amyloid precursors (which are commonly 
intrinsically disordered or partially folded). The discovery of non- 
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covalent ligands specifically for the oligomeric forms of amyloid pro-
teins presents additional challenges, as protein-protein interactions are 
inherently difficult to modulate with small molecules [188]. While small 
molecules have been identified that stabilize natively oligomeric amy-
loid precursors – e.g. the functional tetramers of transthyretin (the ag-
gregation of which results in familial amyloid polyneuropathy) and 
immunoglobulin light chain dimers (involved in light chain amyloid-
osis) [189–192] – the identification of compounds that bind specifically 
to non-native, oligomeric assembly intermediates is far more chal-
lenging: less structural information is available for non-native in-
termediates to guide ligand design and it can be difficult to detect 
oligomer-specific interactions due to the low population of these spe-
cies. Screening methods [193] that are well-suited to the identification 
of oligomer-binding compounds include kinetics approaches, which can 
identify the microscopic events that are modulated by a given compound 
[187], and ESI-MS (sometimes also coupled with IMS), which is suffi-
ciently sensitive to detect lowly-populated intermediates and can iden-
tify the oligomeric state of the ligand-bound species [194]. 
In addition to compounds which are identified through screening, 
small molecules and other ligands which are thought to modulate am-
yloid assembly in vivo can be used in vitro to gain insight into assembly 
pathways. In particular, several metal ions with known or proposed roles 
in amyloid disease have been shown to promote the formation of amy-
loid oligomers [195–197]. A striking example of this was demonstrated 
by Calabrese et al., where Cu2+-mediated stabilization of a β2m variant 
hexamer allowed a high-resolution structure to be obtained of this 
oligomer by X-ray crystallography, showing a ring-like arrangement of 
protomers with a native-like fold (Fig. 2B) [29]. 
For natively disordered amyloid proteins, obtaining discrete olig-
omer populations through non-covalent binding is immensely chal-
lenging, as small molecule or metal ion binding tends to result in a 
distribution of oligomers [159,198–203]. Nonetheless, through bulk 
structural measurements in combination with assays in cells, structure- 
toxicity relationships have been obtained for various natively disordered 
amyloid proteins, including α-synuclein [159,202,203] and Aβ peptides 
[159,200,201,204,205]. 
3.4. Covalent ligands and protein functionalization 
In recent years, covalent modification has become an increasingly 
utilized tool for the modulation of protein-protein interactions 
[206–215]. A covalently bound small molecule may exert an effect on a 
protein or protein complex either via (a) non-covalent interactions 
(which have been reinforced by the covalent bond), or (b) by modifying 
the protein’s surface properties or topography. We will refer to these two 
categories of modifications as “covalent ligands” and “protein func-
tionalization”, respectively. Covalent ligands can offer improved affinity 
and selectivity over their non-covalent analogues [213,216,217], 
thereby overcoming some of the difficulties associated with using small 
molecules to target the dynamic and poorly structured oligomers formed 
by many amyloid proteins. Modification of a protein’s behavior through 
functionalization does not require the conjugated chemical moiety to 
have a high non-covalent affinity for the target; it can instead effectively 
act as a chemical post-translational modification [218,219], altering the 
protein’s surface properties [27,220] or acting as a steric block [30]. We 
also note that sequence variation can be considered as a special case of 
protein functionalization which alters the chemistry and/or steric bulk 
of protein sidechains without the need for chemical modifications to be 
performed post-translationally. The effect of sequence variation on the 
thermodynamic stability of amyloid precursors and oligomers, and on 
the kinetics of protein self-assembly has been extensively studied and 
reviewed elsewhere [29,221–228]. 
Both categories of covalent modification have shown great promise 
in dissecting the structure and toxicity of discrete oligomeric species in 
amyloid assembly, as has recently been demonstrated by a panel of small 
molecules used to stabilize a tetramer formed by the ΔN6 variant of β2m 
[27]. These compounds, which were identified through disulfide teth-
ering [229,230], were found to be capable of modulating ΔN6-β2m 
oligomer populations, primarily by acting as covalent ligands. A series of 
samples was produced where the tetramer population could be varied 
(from ca. 5–95%) based on the site of covalent modification and the 
identity of the small molecule. These samples were used to determine a 
high-resolution structure of ΔN6-β2m tetramers and demonstrate their 
role in inhibiting amyloid fibril formation, through the use of X-ray 
crystallography, solution NMR, and functional assays (Fig. 3A) [27]. The 
ability of such covalent small molecules to generate specific oligomer 
populations in a controlled manner makes this a promising platform to 
study oligomer structures and structure-toxicity relationships for other 
amyloid proteins. 
While the strategies discussed above have focused on methods to 
stabilize particular oligomeric states, sample homogeneity can also be 
improved by destabilizing or preventing the formation of other species 
in an amyloid assembly pathway. For example, the formation of inter- 
peptide backbone hydrogen bonds is essential for fibril formation 
[231] and so blocking the ability of the backbone to form these non- 
covalent interactions provides a means to prevent a protein from 
accessing certain regions of the self-assembly energy landscape. Chem-
ical or steric blocking of backbone hydrogen bonds can be achieved 
through the incorporation of certain backbone mimics, such as the tri-
peptide β-strand mimic “Hao” [232] or through amide N-alkylation 
Fig. 2. Non-covalent strategies for the stabilization of particular oligomer populations, exemplified by nanobody- and metal ion-stabilized β2m oligomers. A: Crystal 
structure of a dimer of a truncated β2m variant (ΔN6-β2m) stabilized by a nanobody (green) [28]. B: Crystal structure of a Cu2+-stabilized hexamer of the H13F β2m 
variant. The Cu2+ ions are colored in orange [29]. In both A and B, β2m protomers are shown in various shades of blue. (For interpretation of the references to color in 
this figure legend, the reader is referred to the web version of this article.) 
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[233]. These approaches have been shown to restrict the self-assembly 
of a range of model amyloid peptides, including those derived from Aβ 
[30,234–236], tau (involved in Alzheimer’s disease and other neuro-
degenerative disorders) [234], β2m [237], and islet amyloid polypeptide 
(IAPP; associated with type II diabetes) [238]. Recently, it has also been 
demonstrated that such covalent modifications can be applied in a 
reversible manner to tune oligomer populations with temporal control. 
The use of photolabile N-2-nitrobenzyl groups in place of (or in com-
bination with) N-alkylation, for example, can allow precise control over 
amyloid oligomer populations, and hence cytotoxicity, of model Aβ 
peptides (Fig. 3B) [30]. The application of this approach to other model 
peptides and full-length amyloid proteins could thus drive novel insights 
into the role of different assembly intermediates and structural features 
in amyloid disease. 
3.5. Crosslinking strategies 
Crosslinking reactions which are rapid and indiscriminate in their 
amino acid preferences offer promising opportunities for capturing 
snapshots of transient oligomers formed by amyloidogenic proteins or 
peptides [242]. Such reaction characteristics are partially or fully 
exhibited by both the photo-induced crosslinking of unmodified proteins 
(PICUP) approach [243] and diazirine-based photochemical cross-
linking [244]. The enhancement of oligomer stability resulting from 
covalent crosslinking renders the assembly intermediates within such 
samples amenable to purification by size separation approaches, 
allowing pure oligomer samples to be prepared for detailed structural 
and functional analysis [239,240,245] (Fig. 3C). 
PICUP is a rapid, radical-based crosslinking method which can be 
used without the need for prior functionalization of the target protein 
with photoreactive groups [246]. Instead, metal complexes (typically 
tris-bipyridyl ruthenium(II)) are oxidized in the presence of visible light 
and subsequently abstract single electrons from amino acid sidechains 
(commonly tyrosine, cysteine, tryptophan, and methionine), rendering 
them capable of forming covalent bonds with suitable proximal residues 
[247]. PICUP has become an established method for the stabilization 
and study of amyloid oligomers [240,248–250], and the purification of 
crosslinked samples to yield individual oligomers has been demon-
strated using a sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) extraction method [239,240] (Fig. 3C). The ability to 
obtain individual samples of well-defined (by mass, if not conforma-
tion), stabilized oligomers through PICUP has allowed the structure and 
toxicity of different Aβ oligomers to be probed. Ono et al. successfully 
isolated crosslinked Aβ40 dimers, trimers, and tetramers (all with at least 
94% purity) and were able to individually characterize the secondary 
structure, amyloidogenicity, and cytotoxicity of each species, ultimately 
finding a correlation between all these variables [239]. With some 
modifications [251], the PICUP crosslinking approach, with subsequent 
oligomer purification, has also been applied to Aβ42 [240]. 
Despite the advantages of PICUP crosslinking chemistry, the 
requirement for an amino acid sidechain radical to encounter a radical 
scavenger or a readily oxidizable sidechain means that intermolecular 
crosslinking between protein molecules can occur through diffusion- 
controlled collision events, independently of genuine protein-protein 
interactions [248]. Such events can be avoided through the use of 
diazirine-based crosslinking, as the carbenes which form upon irradia-
tion of diazirine groups with UV light have nanosecond lifetimes and are 
rapidly quenched by reaction with solvent if no crosslinkable residues 
Fig. 3. Covalent strategies for the control of oligomer 
populations in amyloid protein samples. A: Covalent 
ligands have been shown to be powerful modulators 
of oligomerization equilibria and can allow oligomer 
distributions to be tuned based on the affinity and 
location of the protein-ligand interaction [27]. B: The 
use of photolabile groups (e.g. N-2-nitrobenzyl) to 
sterically or chemically prevent amyloid proteins and 
peptides from accessing particular regions of the self- 
assembly landscape can allow oligomer populations 
to be controlled in a UV-dependent manner [30]. C: 
Covalent crosslinking using the PICUP or diazirine- 
based approaches represents a means of trapping a 
distribution of oligomers formed by a self-assembling 
protein, and the resulting crosslinked species can be 
separated (e.g. by SDS-PAGE, or using other, higher- 
throughput size/mass separation approaches) for in-
dividual structure and toxicity studies [239–241].   
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are in proximity [252]. Although diazirine groups have to be introduced 
into the target protein or peptide by synthesis [25,241,253], covalent 
modification (e.g. via cysteine using methanethiosulfonate- 
functionalized diazirines [254]), or the use of unnatural amino acids 
during protein expression [255,256], the advantages offered by the 
short lifetime of the carbene, the high yield of potential crosslinks 
formed, and the rapidity of their formation when using LED illumination 
(reducing irradiation times from minutes or hours to seconds) [254] 
make diazirines attractive tools for capturing transient amyloidogenic 
interactions [25,241,244,253]. 
In theory, protein photo-crosslinking is well-suited to trap disease- 
relevant oligomers in cells or in vivo, as well as to identify the cellular 
components with which these oligomers interact. However, in practice, 
such an approach presents many challenges, notably the potential for 
very low signal-to-noise ratios due to the vast number of species within 
cells to which an amyloid protein can crosslink, as well as the com-
plexities associated with subsequent data analysis. The use of cross-
linking reagents with extremely short lifetimes and which offer the 
capacity for precise temporal control, such as diazirines, in combination 
with a method for enrichment of the crosslinked species (e.g. through 
affinity tags or alkyne-functionalized crosslinkers) addresses some of 
these challenges. Such an approach, in combination with quantitative 
proteomics has already been shown to be capable of identifying low- 
affinity, non-amyloidogenic protein-protein interactions in living cells 
[257]. Photo-crosslinking thus holds great potential for the study of 
amyloid assembly in physiologically- and disease-relevant systems. 
When attempting oligomer-trapping methods, and particularly 
crosslinking strategies, it is important to keep in mind that while olig-
omer stabilization can dramatically improve sample homogeneity and 
offers advantages for structural characterization, the metastable and 
dynamic nature of amyloid intermediates can also be an important 
characteristic, particularly when considering oligomer toxicity. Olig-
omer dynamics, including protomer dissociation and exchange, can play 
important roles in toxicity [64,258]. While some crosslinked oligomers 
have been observed to undergo detectable dynamic motions [250], in 
other cases, crosslinking has been observed to suppress dissociation 
events which would otherwise contribute towards cell death [259]. It is 
therefore vital to employ a range of approaches to unpick the nature and 
potential cytotoxicity of different oligomers during amyloid assembly, 
keeping in mind that methods which are best suited to generating 
samples for high-resolution structure elucidation and those best suited 
for assessing oligomer toxicity are not necessarily the same. 
4. Conclusion 
Amyloid assembly intermediates are intimately involved in amyloid 
diseases, often representing key cytotoxic species which interact aber-
rantly with each other and other cellular components [11]. While the 
challenges presented by the transient nature, dynamics, and heteroge-
neity of these oligomeric intermediates have hindered structural and 
functional studies, continual advances in biophysical methods and 
chemical tools have allowed increasingly detailed insights to be gained. 
In this review, we have explored the role that NMR and single particle/ 
species methods can play in gaining kinetic and low-resolution struc-
tural descriptions of lowly populated and transient oligomeric in-
termediates. In addition, strategies which allow specific oligomer 
populations to be stabilized (e.g. through the use of antibodies, small 
molecule ligands, or chemical crosslinking) can facilitate higher- 
resolution structural studies and investigation of detailed structure- 
toxicity relationships. It is important, however, to keep a balance be-
tween stabilizing a sample sufficiently to make it amenable to analysis 
through the desired methods and avoiding tipping the oligomerization 
equilibria to biologically- or disease-irrelevant species. The different 
strengths and caveats of the aforementioned methods make all these 
techniques complementary and emphasize the need to employ a wide 
range of integrated methods and tools from chemistry, biophysics, 
structural biology, and cellular biology to gain a complete description of 
these disease-relevant self-assembly pathways and to inform the rational 
design of much-needed treatments. 
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[68] F.S. Ruggeri, T. Šneideris, M. Vendruscolo, T.P.J. Knowles, Atomic force 
microscopy for single molecule characterisation of protein aggregation, Arch. 
Biochem. Biophys. 664 (2019) 134–148, https://doi.org/10.1016/j. 
abb.2019.02.001. 
[69] A. Hoffmann, K. Neupane, M.T. Woodside, Single-molecule assays for 
investigating protein misfolding and aggregation, Phys. Chem. Chem. Phys. 15 
(2013) 7934–7948, https://doi.org/10.1039/c3cp44564j. 
[70] M. Iljina, A.J. Dear, G.A. Garcia, S. De, L. Tosatto, P. Flagmeier, D.R. Whiten, T.C. 
T. Michaels, D. Frenkel, C.M. Dobson, T.P.J. Knowles, D. Klenerman, Quantifying 
co-oligomer formation by α-synuclein, ACS Nano 12 (2018) 10855–10866, 
https://doi.org/10.1021/acsnano.8b03575. 
[71] M. Iljina, G.A. Garcia, A.J. Dear, J. Flint, P. Narayan, T.C.T. Michaels, C. 
M. Dobson, D. Frenkel, T.P.J. Knowles, D. Klenerman, Quantitative analysis of co- 
oligomer formation by amyloid-beta peptide isoforms, Sci. Rep. 6 (2016) 28658, 
https://doi.org/10.1038/srep28658. 
[72] F. Castello, J.M. Paredes, M.J. Ruedas-Rama, M. Martin, M. Roldan, S. Casares, 
A. Orte, Two-step amyloid aggregation: sequential lag phase intermediates, Sci. 
Rep. 7 (2017) 40065, https://doi.org/10.1038/srep40065. 
[73] D.R. Whiten, D. Cox, M.H. Horrocks, C.G. Taylor, S. De, P. Flagmeier, L. Tosatto, 
J.R. Kumita, H. Ecroyd, C.M. Dobson, D. Klenerman, M.R. Wilson, Single- 
molecule characterization of the interactions between extracellular chaperones 
and toxic α-synuclein oligomers, Cell Rep. 23 (2018) 3492–3500, https://doi.org/ 
10.1016/j.celrep.2018.05.074. 
[74] M. Iljina, G.A. Garcia, M.H. Horrocks, L. Tosatto, M.L. Choi, K.A. Ganzinger, A. 
Y. Abramov, S. Gandhi, N.W. Wood, N. Cremades, C.M. Dobson, T.P.J. Knowles, 
D. Klenerman, Kinetic model of the aggregation of alpha-synuclein provides 
insights into prion-like spreading, Proc. Natl. Acad. Sci. U. S. A. 113 (2016) 
E1206–E1215, https://doi.org/10.1073/pnas.1524128113. 
[75] M.H. Horrocks, L. Tosatto, A.J. Dear, G.A. Garcia, M. Iljina, N. Cremades, M. Dalla 
Serra, T.P.J. Knowles, C.M. Dobson, D. Klenerman, Fast flow microfluidics and 
single-molecule fluorescence for the rapid characterization of α-synuclein 
oligomers, Anal. Chem. 87 (2015) 8818–8826, https://doi.org/10.1021/acs. 
analchem.5b01811. 
[76] J. Yang, A.J. Dear, T.C.T. Michaels, C.M. Dobson, T.P.J. Knowles, S. Wu, 
S. Perrett, Direct observation of oligomerization by single molecule fluorescence 
reveals a multistep aggregation mechanism for the yeast prion protein Ure2, 
J. Am. Chem. Soc. 140 (2018) 2493–2503, https://doi.org/10.1021/ 
jacs.7b10439. 
[77] L. Tosatto, M.H. Horrocks, A.J. Dear, T.P.J. Knowles, M. Dalla Serra, 
N. Cremades, C.M. Dobson, D. Klenerman, Single-molecule FRET studies on 
alpha-synuclein oligomerization of Parkinson’s disease genetically related 
mutants, Sci. Rep. 5 (2015) 16696, https://doi.org/10.1038/srep16696. 
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C. Schiene-Fischer, K.G. Reymann, M.T. Stubbs, J. Balbach, M. Görlach, U. Horn, 
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